A study conducted using electronic health record data from a collective of U.S. health care systems found that most adults ...

While medications such as methadone, buprenorphine, and naltrexone are FDA-approved for treating opioid use disorder, they ...

Between 2018 and 2024, China has launched 188 domestically developed innovative drugs – nearly double the number from the ...

RAs, and DPP-4is may offer benefits for patients with COPD, but clinical evidence comparing their effectiveness in reducing ...

While the ongoing Phase I trial is investigating OLX75016 for the treatment of MASH and liver fibrosis, the candidate is also ...

RAs, originally for diabetes, may impact brain health, finding potential benefits for dementia and addiction but inconsistent ...

Researchers had found in a new study that sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 ...

Aardvark’s lead candidate ARD-101 is being investigated in a Phase III study for hyperphagia in Prader-Willi syndrome.

Research reveals semaglutide's effectiveness in decreasing alcohol consumption and cravings, highlighting its potential for ...

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater ...

A recent study found that over a third of websites selling compounded diabetes and weight loss medications, such as Ozempic ...

Cash, cash equivalents, and restricted cash were $26.6M as of December 31, 2024 versus $24.9M as of September 30, 2024. “We are very excited ...